PRA Health Sciences, Inc. (PRAH)
(Delayed Data from NSDQ)
$93.38 USD
+1.38 (1.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $93.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.38 USD
+1.38 (1.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $93.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PRA Health Sciences (PRAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add PRA Health to Your Portfolio Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry.
PRA Health Simplifies Treatment Decisions With Metys Launch
by Zacks Equity Research
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed
by Zacks Equity Research
PRA Health (PRAH) slashes 2019 revenue guidance; direct costs surge in second quarter.
PRA Health Sciences (PRAH) Beats Q2 Earnings Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 1.67% and -0.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
by Zacks Equity Research
Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.
PRA Health Sciences (PRAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
PRA Health Sciences (PRAH) Down 5.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.
PRA Health Sciences (PRAH) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 3.77% and -1.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
PRA Health Sciences (PRAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Growth Stocks to Buy for April 24th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 24th.
Top Ranked Growth Stocks to Buy for April 22nd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 12th.
Top Ranked Growth Stocks to Buy for April 18th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 18th
Top Ranked Growth Stocks to Buy for April 12th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 12th.
PRAH vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PRAH vs. HQY: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for April 4th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 4th
Top Ranked Growth Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 2nd
Looking for a Growth Stock? 3 Reasons Why PRA Health Sciences (PRAH) is a Solid Choice
by Zacks Equity Research
PRA Health Sciences (PRAH) could produce exceptional returns because of its solid growth attributes.
PRA Health Sciences (PRAH) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc to Acquire MedecinDirect, Expand Overseas Business
by Zacks Equity Research
Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.
PRAH vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PRAH vs. HQY: Which Stock Is the Better Value Option?
3 Reasons Growth Investors Will Love PRA Health Sciences (PRAH)
by Zacks Equity Research
PRA Health Sciences (PRAH) could produce exceptional returns because of its solid growth attributes.
Encouraging Near-Term Outlook for Medical Services Industry
by Urmimala Biswas
With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.